Polaris

More documents

Recommendations

Info

CompanyMaster Subject LogProtocol #:Study Title:Investigator:Site Address:Sponsor:SubjectnumberSubject Name and AddressPhone and E-mailDate ofBirthSocial SecurityNumberDateHome: Enrolled:Work: Completed:E-mail: Discontinued:Home: Enrolled:Work: Completed:E-mail: Discontinued:Home: Enrolled:Work: Completed:E-mail: Discontinued:Home: Enrolled:Work: Completed:E-mail: Discontinued:Home: Enrolled:Work: Completed:E-mail: Discontinued:Patient Master.doc© 2004 by CRC Press LLC
Page 2:
HANDBOOK OFSOPs FOR GOODCLINICAL PR
Page 10:
About PolarisClinical Research Cons
Page 14:
Table of ContentsMON-001.0MON-002.0
Page 18:
Initial SubIRB MemberMinutes Templa
Page 22:
SOP# MON-001.0CompanyEffective Date
Page 26:
CompanyStandard Operating Procedure
Page 30:
Page 34:
Page 38:
Page 42:
Page 46:
Page 50:
Page 54:
Page 58:
Page 62:
Page 66:
Page 70:
Page 74:
Page 78:
Page 82:
Page 86:
Page 90:
Page 94:
Page 98:
Page 102:
Page 106:
Page 110:
Page 114:
Page 118:
Page 122:
Page 126:
Page 130:
Page 134:
Page 138:
Page 142:
Page 146:
Page 150:
SOP# SITE-001.0CompanyEffective Dat
Page 154:
Page 158:
SOP# SITE-002.0F. Retention of Trai
Page 162:
Page 166:
Page 170:
Page 174:
Page 178:
Page 182:
Page 186:
Page 190:
Page 194:
Page 198:
Page 202:
Page 206:
Page 210:
Page 214:
Page 218:
Page 222:
Page 226:
Page 230:
Page 234:
SOP# SITE-013.0E. Sponsor ContactsC
Page 238:
Page 242:
SOP# SITE-014.0V. AttachmentsNoneCo
Page 246:
SOP# IRB-001.0CompanyEffective Date
Page 250:
Page 254:
Page 258:
Page 262:
Page 266:
Page 270:
Page 274:
Page 278:
Page 282:
Page 286:
Page 290:
Page 294:
Page 298:
Page 302:
Page 306:
Page 310:
Page 314:
Page 318:
Page 322:
CompanyProtocol Amendment FormProto
Page 326:
CompanyCRF Review FormProtocol #: I
Page 330:
CompanyDrug Dispensing LogDrug name
Page 334: CompanyClinical Trial Materials Dis
Page 338: CompanyInvestigational Product Rece
Page 342: CompanyScreening and Enrollment Log
Page 346: CompanyExpedited Review FormStudy I
Page 350: CompanySubject Information and Cons
Page 354: CompanySubject Information and Cons
Page 358: CompanyStudy Initiation Document Tr
Page 362: CompanyInitial Submission Form (con
Page 374: CompanyIRB Membership RosterMultipl
Page 378: CompanyRecommendations (number the
Page 382: CompanyThe meeting adjourned at --:
Page 388: SubjectnumberSubject Name and Addre
Page 392: CompanyIRB Progress Report FormProt
Page 396: CompanyStudy Responsibilities FormP
Page 400: CompanyReviewer’s ChecklistProtoc
Page 404: CompanyIRB Review Results FormPropo
Page 408: Code INTENSITY as:1 = Mild2 = Moder
Page 412: CompanySerious Adverse Subject Init
Page 416: CompanySafety Information FormProto
Page 420: CompanyStudy Signature Sheet (contd
Page 424: CompanyIRB Notification of Study Te
Page 428: CompanyTraining Plan FormEmployee:S
Page 432: CompanyEmployeeProject-specific tra
Page 436:
CompanyStaff Training Request FormE
Page 440:
CompanySite Evaluation Visit Trip R
Page 444:
CompanyOverall Assessment (continue
Page 448:
CompanyMEETING CONTENTINDICATE WHIC
Page 452:
CompanyPeriodic Site Visit Trip Rep
Page 456:
CompanySERIOUS ADVERSE EXPERIENCESS
Page 460:
CompanyStudy Termination Visit Trip
Page 464:
CompanyStudy Drug (continued)Yes No
Page 468:
CompanyMeeting with InvestigatorDid
show all

Polaris

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?